Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lerociclib + Osimertinib in EGFR+ Metastatic NSCLC
NCT03455829Phase 2Completed
- Sponsor
- G1 Therapeutics, Inc.
- Start
- Mar 2018
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lerociclib in non-small cell lung cancer (NSCLC), sponsored by G1 Therapeutics, Inc.. Started Mar 2018; status: completed.
02
Drugs
lerociclib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03455829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03455829.